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Purpose or Objective: To evaluate biochemical progression-
free survival (BDFS) in men 60 years of age or younger with 
prostate cancer who underwent exclusive permanent 
brachytherapy 
 
Material and Methods: 528 patients(p) with LR/IR. T1:423p 
T2: 105p; Gleason 6: 520p, gleason 7: 8p; neoadyuvant 
hormonotherapy: 48p.; initial PSA≤10: 492p, > 10: 36p. Md 
follow-up 63m (1-173m). BDFS was defined ASTRO definition. 
Patients were selected from RECAP database, helped by 
URONCOR and GEG groups. 
 
Results: Dosimetry: pD90: md147 Gy (45-215 gy); pD90 > 165 
Gy: 19.8%; pD100: md86.2 Gy; pV150: md54.6% prostate 
volumen: 36 cc (14-93 cc) . D10 urethra: md142%(112-191 %); 
D2cc rectum: 79.2 %.Toxicity: Acute: genitourinary: g2: 6.1%; 
g3: 0.6%; rectal: g2: 20%, g3: 3.7%. Late: genitourinary: g2: 
7.7%; g3: 4.6%; rectal: g2: 2%, g3: 0.5%. Both were related 
with pV150: Acute GUg≥2: 71.7% (pV150> 50%) vs. 28.1% 
(<50%); late GUg≥2: 81.8% (> 50%) vs. 18.2% (<50%). p:ns. For 
the entire group, 40p had biochemical failure; 25p localF, 7p 
regionalF and 5p metastases and 5 p (1.05%) dead with 
prostate cancer. The actuarial 5-year and 10-y BDFS was 
93.2% and 88.7%. Overall survival at 5y: 97.3% and 10y: 
91.7%. No factor had influence in the analysis of prognostic 
factors of BDFS. However BDFS 10y pD90 < 145 Gy: 86% vs. 
D90 145-165Gy: 87.8% vs. D90 > 165 Gy: 92.5% (HR: 1.47, p: 
0.46). 
 
Conclusion: This is one of the biggest series at the moment 
in younger men with permanent brachytherapy. Patients 60 
years of age or younger have a high probability of 10-year 
BDFS. There is a trend to get better results with D90> 165 Gy. 
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Purpose or Objective: To investigate the interobserver 
variability in contouring of rectum in high-dose rate 
brachytherapy (HDRBT) for the treatment of prostate 
carcinoma. The HDV dosimetric parameters are obtained and 
reported in accordance with the GEC/ESTRO 
recommendations. 
 
Material and Methods: Four blinded observers 
retrospectively contoured the rectum of five patients treated 
with HDRBT in the radiation oncology department. A 
contouring consensus was previously established to agree in 
the anatomical limits determination in the rectal contouring. 
HDV dosimetric parameters analyzed were the included on 
the GEC-ESTRO recommendations: D0.1cc, D1cc and D2cc and 
the rectal volume were calculated. These endpoints were 
compared between and within the observers. The coefficient 
of variation (CV) defined as a measure of the spread of data 
as a proportion of its mean (expressed as a percentage), was 
estimated to assess the interobserver variation. For each 
parameter, the mean and SD of the two measurements 
recorded (taken with one week apart) from the treatment 
planning study made by transrectal ultra-sonogram (TRUS) 
were estimated for each of the 4 observers. The effect of 
interobserver variation in the total dose recorded was 
analyzed by estimating the accumulative dose (EQD2) for the 
rectum. For our study, the dosimetric parameter to rectum 
was evaluated regarding to single 15Gy prostate HDRBT plan 
and assuming that rectum received full-dose EBRT (46 Gy). 
The total EQD2 (equivalent dose in  
2 Gy per fraction, assuming alpha/beta ratio of 3) doses were 
estimated. 
 
Results: The patient data are represented in Table 1 showing 
the results of the mean reported D0.1cc, D1cc and D2cc for 
the rectum contoured twice for each case. The interobserver 
coefficient of variation for reported D0.1cc, D1cc and D2cc 
was 5.7%(SD 6,28), 4.5%(SD 1,94) and 4%(SD 2,24), 
respectively. The total D2cc parameter for the patients with 
the highest interobserver variation in rectum delineation, 
may result in recorded rectum dose difference up to 2,6 Gy 
by EQD2. 
 
 
 
Conclusion: Interobserver variations in reported parameters 
were high for the D0.1cc (CV: 16%) in a worst-case scenario. 
Even if the D2cc parameter corresponds to low interobserver 
variation, we found that the greatest variation is present in 
high prostate volume cases. Variation in delineation of the 
rectum may be a potential source of uncertainty in the BT 
planning and delivery process. Nevertheless, in our study the 
impact of interobserver variation on the total dose (EQD2) for 
the reported D2cc has a mean of +/- 1.5 Gy. This study 
represents a small analysis of a single center experience, but 
it will be completed with a multicenter study in a second 
part. 
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Purpose or Objective: High Dose Rate Brachytherapy (HDR-
BT) as stand-alone treatment is gaining popularity as salvage 
strategy for patients (pts) with an isolated, intraprostatic 
Prostate Cancer (PCa) recurrence after External Beam 
Radiotherapy (EBRT) and may represent the only treatment 
available for the management of pts diagnosed with PCa and 
challenging clinical scenarios (for ex, pts previously 
irradiated in the pelvis for other primaries). We present a 
retrospective analysis of our series of PCa pts managed with 
HDR-BT alone with particular emphasis on dosimetry and 
early toxicity results. 
 
Material and Methods: From March 2014 to June 2015, 13 pts 
have been treated with HDR-BT alone in our centre: nine 
with salvage intent for an intraprostatic relapse after EBRT, 
and four for primary management after pelvic EBRT for other 
malignancies (follicular lymphoma, rectal cancer and B-cell 
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lymphoma). All patients had biopsy-proven disease and got 
pre-treatment local and distant staging (Choline PET-CT, 
pelvic/prostatic MRI and bone scan). HDR-BT was performed 
by transperineal insertion of intraprostatic catheters under 
spinal anaesthesia and trans-rectal ultrasound guidance using 
an Ir-192 source. A total dose of 24 Gy to the whole gland 
was prescribed in two separate fractions of 12 Gy, 2-4 weeks 
apart. Dosimetric constraints for prostate and organ at risk 
(OAR) sparing were defined; we aimed at a prostate D90 > 
95% and a V100 > 85% while the urethral Dmax was kept < 120 
% and the D10 < 115 %; the rectal D2cc was kept <75 %. 
Patient reported genitourinary (GU) and gastro-intestinal (GI) 
symptoms according to the NCI.CTCv3 were assessed before 
HDR-BT and every 4-6 months afterward. 
 
Results: The median age of the pts was 68.5 (range 63-77) 
years; the pre-treatment PSA was 5.71 (range 0.067-11.04) 
ng/ml. The median interval from the end of the previous 
EBRT and HDR-BT was 8.75 (range 3-16 years) years. The 
median prostate D90 and V100 for the 26 HDR-BT fractions 
analysed were respectively 97.17 % and 86.7 % of the 
prescribed dose but in 4 pts the D90 was < 95 % and in 8 the 
V100 was < 85 %. The median urethral Dmax was 105.73 % 
and the median D10 was 94.71 %; the median D2cc for the 
rectum was 45.98 %. After a median follow-up of 13.9 (range 
2-28) months, acute GU grade 1 and 2 toxicities were 
reported in 4 and 3 pts respectively while one patient 
reported a grade 2 acute GI toxicity. Eleven pts were 
evaluable for late toxicities: five reported a late GU grade 1 
and two pts a grade 2 toxicity. Any late GI toxicity has been 
reported so far. Nine pts (69%) are biochemical disease-free 
while none of the 4 pts showing a rising PSA developed an 
intraprostatic relapse. 
 
Conclusion: HDR-BT in 2 fractions of 12 Gy may represent an 
interesting alternative for the management of pts with an 
isolated intraprostatic recurrence after EBRT and for 
challenging clinical situations when EBRT is contraindicated. 
The early toxicity profiles seem correct and clinical results 
promising. 
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Purpose or Objective: The aim is to compare OAR dosimetry 
for the nationally-adopted technique for PSB withexisting 
GEC-ESTRO and ABS guidelines. This modified MountSinai 
technique prescribes 160Gy to the prostate gland without a 
margin. Thedose volume constraints (DVCs) used are: 
urethra(UD30) < 181Gy and rectum (RV100) < 1cc.  
By comparing the institutional techniqueto international 
standards we aim to demonstrate if: 
i) All constraints perform similarly usingclinical plans. 
ii) Institutional plans would be consideredreasonable when 
GEC-ESTRO and ABS guidelines are applied. 
iii) The addition of GEC-ESTRO and ABS DVCsto institutional 
practice may be of clinical utility. 
 
Material and Methods: The first 50 PSB implants performed 
in Institution were retrospectively re-contoured as per ABS 
and GEC ESTRO recommendations in Variseed (version 8.0). A 
PTV with margin of 3mm was added to the prostate except 
posterior aspect. The prescribed dose was altered to 145Gy 
to the PTV, as per GEC-ESTRO and ABS guidelines. The GEC-
ESTRO and ABS DVCs were then applied. 
 
Results: The median prostate V100 was 95.34% for CUH (IQR 
95.34-97.66%) met by 58% of cases. The median V100 was 
94.17% for ABS and GEC-ESTRO (IQR 92.68-95.61%) met by 
36% of cases (p=0.007). The median D90 for CUH was 
175.46Gy (IQR 168.98-186.67Gy). The median D90 for GEC-
ESTRO and ABS was 159.08Gy (IQR 152.46-165.41Gy). 
D90>prescription dose was achieved by 92% for all groups. 
The median RV100 using the institutional technique was 
0.27cc (IQR 0.12-0.59cc) and the <1cc target was met by 92% 
of cases. The ABS rectal constraint is RV100<1.3cc, at day 30. 
The median ABS RV100 was 0.46cc (IQR 0.28-0.91cc) and the 
<1.3cc target was achieved in 88% of cases. The GEC-ESTRO 
rectal constraint D0.1<200Gy and D2cc≤145Gy were met by 
70% and 100% of the plans respectively. The median urethral 
UD30 using the institutional technique was 178.10Gy (IQR 
175.27-180.59Gy). The GEC-ESTRO urethral constraints of 
UD30<188.5Gy and D10<217.5Gy were met by 100% and 100% 
of plans respectively. The ABS urethral constraint UD5<150% 
was met by 98% and UD30<125% was met by 82% of cases. 
 
Conclusion: Comparing the Institutional DVCs for rectum and 
urethra with ABS and GEC-ESTRO guidelines shows that they 
are concordant. Institutional and ABS urethral constraint 
UD30 appears conservative when GEC-ESTRO urethral 
constraints are applied. While validated DVCs are vital for 
optimal prostate seed brachytherapy, prospective 
documentation of toxicities is crucial. 
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Purpose or Objective: The aim of this study is to examine if 
adjuvant hormonal therapy is needed for all of the high-risk 
prostate cancer patients treated with high dose rate-
brachytherapy (HDR-BT) combined with external beam 
radiotherapy (EBRT). 
 
Material and Methods: Between July 1999 and June 2010, 
121 patients considered as high-risk group (T stage > or = 2c, 
PSA > 20 ng/ml, or Gleason score (GS) > or = 8) were treated 
with HDR-BT and EBRT at Kochi Medical School Hospital in 
Japan. Patient age ranged from 52 to 82 (median 71) years 
old. Eighty-two patients had received neoadjuvant hormonal 
therapy, which was stopped at the beginning of radiotherapy 
in all cases. Patients were treated with EBRT to 40 Gy in 20 
fractions or 39 Gy in 13 fractions and HDR-BT to 18 Gy in 2 or 
3 fractions for prostate and seminar vesicle. Adjuvant 
hormonal therapy was not performed until biochemical 
failure or clinical recurrence became apparent. PSA failure 
was defined as the Phoenix definition of nadir + 2 ng/mL. The 
overall survival (OS) rates, disease-specific survival (DSS) 
rates, and biological relapse-free survival (bRFS) rates were 
estimated using the Kaplan-Meier method. Log-rank test and 
Cox proportional hazards regression analysis were used for 
univariate and multivariate analyses, respectively, to 
examine these factors in relation to bRFS: age, clinical T 
stage (cT), initial PSA level (iPSA), GS, needle core biopsy 
positive ratio (% core), and use of neoadjuvant hormonal 
therapy (NHT). Follow-up ranged from 4 years 3 months to 13 
years 3 months (median 6 years 10 months). 
 
Results: The 5-year OS, CSS, and bRFS rates were 91.3, 98.2, 
and 88.0%, respectively. The 7-year OS, CSS, and bRFS rates 
were 86.4, 98.2, and 88.0%, respectively. In log-rank test, 
the group with cT < or = 2b was superior to that with cT > or 
= 2c (p = 0.0297), and that with iPSA < or = 10 ng/mL was 
superior to that with iPSA > 10 ng/mL (p = 0.0137). On 
multivariate Cox regression analysis, cT remained an 
independent predictor of bRFS (hazard ratio, 3.82; 95% 
confidence interval [CI], 1.11-13.14; p = 0.0337). 
 
Conclusion: In the high risk prostate cancer group treated 
with HDR-BT followed by EBRT, the subgroup with cT < or = 
2b gained a good bRFS rate without adjuvant hormonal 
therapy. 
 
 
 
